News >

Nivolumab Shows Promise in Mesothelioma

Virginia Powers, PhD
Published: Wednesday, Dec 14, 2016

Paul Baas, MD, PhD

Paul Baas, MD, PhD

Treatment with the PD-1 inhibitor nivolumab (Opdivo) showed promising results in patients with recurrent malignant pleural mesothelioma (MPM), according to findings from the phase II Nivo-Mes trial presented at the 17th World Lung Cancer Conference in Vienna.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x